"Sparfloxacin"

Sparfloxacin An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationNo information is available on the use of sparfloxacin during breastfeeding. Fluoroquinolones have traditionally not been used in infants because of concern about adverse effects on the infants' developing joints. However, recent studies indicate little risk.[1,2] The calcium in milk might prevent absorption of the small amounts of fluoroquinolones in milk,[3

Comparison of the Antimicrobial Efficacy of Two Antibiotics Sparfloxacin and Augmentin as Experimental Root Canal Irrigating Solutions against Enterococcus faecalis - An Invitro Study One of the main goals of endodontic treatment is root canal disinfection and to prevent subsequent chances of reinfection. Adjuvant to instrumentation, root canal irrigants are required to eliminate the bacteria found on the root canal walls and lateral canals within the dentinal tubules. To measure and compare the antibacterial efficacy of two antibiotics as experimental root canal irrigating solutions against Enterococcus faecalis (E. faecalis). Fifteen Brain Heart Infusion agar plates were inoculated with Enterococcus faecalis-American Type Culture Collection (ATCC) 29212. 5 micrograms (mcg) Sparfloxacin

Crystal structures of [Mn(bdc)(Hspar)2(H2O)0.25]·2H2O containing MnO6+1 capped trigonal prisms and [Cu(Hspar)2](bdc)·2H2O containing CuO4 squares (Hspar = sparfloxacin and bdc = benzene-1,4-di­carboxyl­ate) The syntheses and crystal structures of 0.25-aqua-(benzene-1,4-di-carboxyl-ato-κ(2) O,O')bis-(sparfloxacin-κ(2) O,O')manganese(II) dihydrate, [Mn(C8H4O4)(C19H22F2N4O3)2(H2O)0.25]·2H2O or [Mn(bdc)(Hspar)2(H2O)0.25]·2H2O, (I), and bis-(sparfloxacin-κ(2) O,O')copper(II) benzene-1,4-di-carboxyl-ate dihydrate, [Cu(C19H22F2N4O3)2](C8H4O4)·2H2O or [Cu(Hspar)2](bdc)·2H2O, (II), are reported (Hspar = sparfloxacin and bdc = benzene-1,4-di-carboxyl-ate). The Mn(2+) ion in (I) is coordinated by two O,O'-bidentate Hspar neutral mol-ecules (which exist as zwitterions) and an O,O'-bidentate bdc

Complete Genome of the Attenuated Sparfloxacin-Resistant Streptococcus agalactiae Strain 138spar Through the selection of resistance to sparfloxacin, an attenuated Streptococcus agalactiae strain, 138spar, was obtained from its virulent parent strain, S. agalactiae 138P. The full genome of S. agalactiae 138spar is 1,838,126 bp. This genome will allow comparative genomics to identify genes

Role of pentoxifylline and sparfloxacin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients. This study was directed to evaluate the role of sparfloxacin and pentoxifylline in the prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients. Forty cirrhotic patients with ascites were included in the study. Patients were randomized into four groups in a blind fashion; each group consists of ten patients. Group one received ciprofloxacin (control group), group two received sparfloxacin, group three received pentoxifylline, and group four received a combination of sparfloxacin and pentoxifylline. Treatment duration was six months. Serum TNF- α level was the primary inflammatory marker of the study to evaluate the effect of the used medications. In group two

Clinical evaluation of the tolerability and efficacy of trovafloxacin compared with sparfloxacin in the treatment of lower respiratory tract infections. To evaluate the clinical tolerability and efficacy of trovafloxacin compared with sparfloxacin in the treatment of lower respiratory tract infections. This was a randomised, double-blind, controlled, parallel study. 92 patients with lower respiratory tract infection were enrolled in three centres. 45 patients received trovafloxacin 200mg once daily orally for 10 days and 43 patients received sparfloxacin 400mg on the first day and 200mg once daily orally for 9 days. Clinical evaluation was performed for fever, dyspnoea, pulmonary symptoms, cough and sputum on days 1, 3, 6 and 12 of the study along with bacteriological evaluation on days 1

, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000; 45: 231-233. * 25. Saito H, Ishii N. Antibacterial activities of new fluoroquinolones against Mycobacterium ulcerans. J Antimicrob Chemother 2001; 47 Suppl 1: 30. * 26. O’Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of Mycobacterium ulcerans osteomyelitis

Database (...]Review Sparfloxacin.[Drugs and Lactation Database (...]See reviews...See all...Recent ActivityClearTurn OffMoxifloxacin - Drugs and Lactation Database (LactMed®)See more...FOLLOW NCBIConnect with NLM National Library of Medicine8600 Rockville PikeBethesda, MD 20894Web PoliciesFOIAHHS Vulnerability DisclosureHelpAccessibilityCareersNLMNIHHHSUSA.gov

and Lactation Database (LactMed) - GlossaryLactMed Selected ReferencesDrugs and Lactation Database (LactMed) - About Dietary SupplementsBreastfeeding LinksRelated informationPubChem SubstancePubMedSimilar articles in PubMedReview Moxifloxacin.[Drugs and Lactation Database (...]Review Ciprofloxacin.[Drugs and Lactation Database (...]Review Ofloxacin.[Drugs and Lactation Database (...]Review Sparfloxacin.[Drugs

.[Drugs and Lactation Database (...]Review Moxifloxacin.[Drugs and Lactation Database (...]Review Norfloxacin.[Drugs and Lactation Database (...]Review Delafloxacin.[Drugs and Lactation Database (...]Review Sparfloxacin.[Drugs and Lactation Database (...]See reviews...See all...Recent ActivityClearTurn OffGemifloxacin - Drugs and Lactation Database (LactMed®)See more...FOLLOW NCBIConnect with NLM

and Lactation Database (...]Review Moxifloxacin.[Drugs and Lactation Database (...]Review Norfloxacin.[Drugs and Lactation Database (...]Review Sparfloxacin.[Drugs and Lactation Database (...]See reviews...See all...Recent ActivityClearTurn OffCiprofloxacin - Drugs and Lactation Database (LactMed®)See more...FOLLOW NCBIConnect with NLM National Library of Medicine8600 Rockville PikeBethesda, MD 20894Web

and Lactation Database (LactMed) - GlossaryLactMed Selected ReferencesDrugs and Lactation Database (LactMed) - About Dietary SupplementsBreastfeeding LinksRelated informationPubChem SubstancePubMedSimilar articles in PubMedReview Lomefloxacin.[Drugs and Lactation Database (...]Review Sparfloxacin.[Drugs and Lactation Database (...]Review Enoxacin.[Drugs and Lactation Database (...]Review Ciprofloxacin.[Drugs

.[Drugs and Lactation Database (...]Review Enoxacin.[Drugs and Lactation Database (...]Review Sparfloxacin.[Drugs and Lactation Database (...]Review Lomefloxacin.[Drugs and Lactation Database (...]Review Trovafloxacin.[Drugs and Lactation Database (...]See reviews...See all...Recent ActivityClearTurn OffDelafloxacin - Drugs and Lactation Database (LactMed®)See more...FOLLOW NCBIConnect with NLM

and Lactation Database (LactMed) - About Dietary SupplementsBreastfeeding LinksRelated informationPubChem SubstancePubMedSimilar articles in PubMedReview Alatrofloxacin.[Drugs and Lactation Database (...]Review Lomefloxacin.[Drugs and Lactation Database (...]Review Moxifloxacin.[Drugs and Lactation Database (...]Review Sparfloxacin.[Drugs and Lactation Database (...]Review Enoxacin.[Drugs and Lactation

) - GlossaryLactMed Selected ReferencesDrugs and Lactation Database (LactMed) - About Dietary SupplementsBreastfeeding LinksRelated informationPubChem SubstanceSimilar articles in PubMedReview Misoprostol.[Drugs and Lactation Database (...]Review Sparfloxacin.[Drugs and Lactation Database (...]Review Difluprednate.[Drugs and Lactation Database (...]Review Diflunisal.[Drugs and Lactation Database (...]Review